Hypothesis Colonic senescent fibroblasts drive age‑related gut barrier leakiness, which amplifies dysbiotic signaling to the brain via vagal and humoral routes; clearing these cells with a senolytic restores barrier function, normalizes the microbiota‑brain axis, and improves cognition.

Mechanistic Rationale Aging microbiota loses SCFA producers and gains pro‑inflammatory taxa[1]. This shift alone does not fully explain the magnitude of systemic inflammation observed. Recent work shows that senescent stromal cells in the colonic lamina propria secrete SASP factors (IL-6, MMP-9) that disrupt tight junction proteins[2]. The resulting barrier breach allows luminal LPS and microbial metabolites to reach systemic circulation, activating brain microglia through TLR4 and vagal afferents[3]. Thus, the microbiome ages the host, but the host’s senescent stroma determines how strongly that signal is transmitted.

Novel Insight We propose that the senescent fibroblast compartment is the 'hardware' limit that gates microbiome‑derived inflammaging. Even a youthful microbiota cannot provoke neuroinflammation if the barrier is intact; conversely, a pro‑inflammatory microbiota has limited impact when senescent cells are removed.

Testable Predictions

1. Aged mice treated with a fibroblast‑specific senolytic (e.g., FOXO4-DRI conjugated to a fibroblast‑targeting peptide) will show ↓ colonic p16^INK4a^+ cells, ↑ zonulin-1 and occludin expression, and reduced serum LPS-binding protein.
2. Microbiota composition (16S rRNA sequencing) will remain aged‑like, yet serum cytokine profile (IL-1β, TNF-α, IL-6) will shift toward youthful levels.
3. Vagal firing rates recorded from the subdiaphragmatic vagus will decrease, reflecting lower afferent inflammatory tone.
4. Cognitive performance in the Morris water maze will improve to levels comparable to young controls, despite unchanged fecal microbial diversity.
5. Germ‑aged mice receiving fecal transplant from senolytic‑treated aged donors will not acquire the cognitive benefit, confirming that the effect is host‑mediated rather than microbiota‑mediated.

Experimental Design

• Use 20‑month‑old C57BL/6 mice, n=10 per group.
• Groups: (a) vehicle control, (b) systemic senolytic (navitoclax) as positive control, (c) fibroblast‑targeted senolytic, (d) fibroblast‑targeted senolytic + broad‑spectrum antibiotics to deplete microbiota.
• Administer treatments twice weekly for 4 weeks.
• Endpoints: colonic immunohistochemistry for p16^INK4a^ and α-SMA, qPCR for tight‑junction genes, serum LPS‑binding protein and cytokines, vagal electrophysiology, 16S rRNA sequencing, behavioral testing (Y‑maze, novel object recognition).
• Include sham‑operated young (4‑month) mice as baseline.

Potential Outcomes & Interpretation If fibroblast‑targeted senolysis restores barrier integrity and improves cognition without reshaping the microbiota, the hypothesis is supported. If cognition improves only when microbiota is also altered (antibiotics group), then the microbiome remains a necessary driver, challenging the primacy of stromal senescence. Lack of effect would falsify the claim that colonic fibroblasts are a critical gate.

Implications This work would shift therapeutic focus from sole microbiome modulation to combined senolytics that preserve gut epithelium, offering a hardware‑software co‑intervention strategy for inflammaging‑related cognitive decline.

References [1] https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1704047/full [2] https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2025.1667448/full [3] https://www.vjdementia.com/video/v8axgprwi5y-how-does-the-gut-microbiota-affect-neuroinflammation-in-alzheimers-disease/